UNH vs ZVRA

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Score Change Explanation: The previous analysis (2026-03-30, score 9.2/10) heavily weighted the 'significantly de-risked' future approval of Arimoclomol (Niemann-Pick Type C) with a mid-2026 PDUFA date and a 'strong pipeline'. However, updated real-time intelligence reveals material shifts: 1) Zevra has pivoted to a 'single-asset (MIPLYFFA) focus' by selling its SDX portfolio, significantly reduci...